NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
Advertisement
NewsRx | Free Trials
Advertisement
----------
------------
NewsRx on Facebook
-----
Press Release Submissions
PR Login
*
*

Women's Health Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Breast Cancer



Concurrent use of trastuzumab and chemotherapy significantly reduces recurrence



June 9th, 2005

A study led by a Mayo Clinic researcher in Jacksonville, Florida, and conducted by the North Central Cancer Treatment Group (NCCTG) has provides important new data about the effectiveness and safety of a breast cancer treatment combining chemotherapy and the monoclonal antibody trastuzumab (Herceptin).

According to Mayo Clinic medical oncologist and NCCTG study chair Edith Perez, MD, these results could change the standard of care for thousands of women with breast cancer.

"Women with HER-2 positive breast cancer had a high risk of the cancer returning and of dying from breast cancer. This intervention - chemotherapy plus trastuzumab - essentially...


Source: Women's Health Weekly (2005-06-09)

NewsRx Passes
Advertisement
More Articles

------------------------
Security by Verisign PR Login